AREVA Med to expand production capacities in the U.S.

November 03, 2014

AREVA Med announced today plans to build a new production facility in the United States.  The company has acquired land in Plano, Texas, for the future site of a new facility for lead-212 production for use in medical applications.  This site will also serve as the new offices and laboratory for AREVA Med’s subsidiary Macrocyclics, Inc., the global leader of chelating agent technology. 

This new facility will increase the company’s production capabilities to meet the growing need of lead-212 for clinical developments of new cancer treatments in North America.  It builds upon the existing lead-212 production capacities of the AREVA Med Maurice Tubiana Facility, located in Bessines-sur-Gartempe in the Limousin region of France, which has been in operation since 2013. 

 Patrick Bourdet, CEO of AREVA Med, said: “The construction of this new comprehensive facility in Plano will reinforce our presence and our proximity to our key partners in the United States. In addition to our production activities in France, we will be able to manufacture and distribute lead-212 locally to support the development of innovative, targeted, and powerful lead-212 treatments to combat cancer.” 

More information at www.arevamed.com, @AREVAmed, www.macrocyclics.com, and www.targetedtrials.com

 

AREVA Med Video

Click here to view the latest AREVA Med Video

Contact

For more information about AREVA Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673